|
Formulary coverage is now available for LIVTENCITY® in Alberta
|
|
|
FORMULARY COVERAGE IS NOW AVAILABLE FOR LIVTENCITY® IN ALBERTA
(RESTRICTIONS APPLY)
|
|
|
Dear Dr. Smith,
|
LIVTENCITY is the first and only treatment with an indication for adults with refractory post-transplant cytomegalovirus (CMV) infection1*
|
|
We’re pleased to announce that LIVTENCITY is now on the Alberta Formulary as a special authorization drug.
|
|
LIVTENCITY (maribavir) is indicated for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.2
|
|
|
|
|
LET’S TALK ABOUT LIVTENCITY
|
|
I would be happy to connect with you soon to talk more about LIVTENCITY.
|
|
|
|
Please consult the product monograph at https://takeda.info/en-ca-livtencitypm/ for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by calling us at 1‑800‑268‑2772.
|
|
Best regards,
RBM Name
RBM Email Address
RBM Phone Number
|
* Comparative clinical difference has not been established.
1. Data on File. Takeda Canada. February 8th 2023.
2. PrLIVTENCITY® (maribavir tablets) Product Monograph. Takeda Canada Inc. September 23, 2022.
|
|
|
|
|
Takeda Canada Inc.
www.takeda.com/en-ca
LIVTENCITY and  are registered trademarks of Takeda Pharmaceuticals International AG.
TAKEDA and are registered trademarks of Takeda Pharmaceutical Company Limited, used under license.
© 2024 Takeda Pharmaceutical Company Limited. All rights reserved.
PRMCDA/CA/LIV/0021
|
This email is intended for Canadian healthcare professionals only.
If you wish to stop receiving email notifications from Takeda Canada Inc., unsubscribe.
You can also learn about the information that we may process about you and how we use your information here.
|
|
